CASSS – Sharing Science Solutions is pleased to announce Mark Schenerman, President, CMC Biotech-MAS Consulting, and Sarah Kennett, Executive Director, Regulatory Expert, Pharma Technical Regulatory, Genentech, a Member of the Roche Group, respectively, have been elected President and Vice President to the CASSS Board of Directors. CASSS board officers are elected by their fellow board members to two-year terms.
According to Mark Schenerman, “CASSS is poised to build on its legacy as an agile, global community of scientific and regulatory professionals by continuing to innovate meeting formats, elevate emerging topics, and expand opportunities for collaboration that advance biopharmaceutical development. Over the coming years, CASSS will refine and articulate a clear vision for its future—spanning two, five, and ten years—with input from members, visionary leaders in regulatory science, and stakeholders across industry and academia. Key initiatives include developing a refreshed brand strategy and launching an enhanced WCBP experience beginning in 2028 at its new home in the Westin Downtown DC, a space designed to support growth, creativity, and deeper engagement. Through this evolution, CASSS remains committed to integrating diverse perspectives, fostering scientific excellence, and ensuring that its programs continue to meet the evolving needs of the community and ultimately benefit patients worldwide.”
Schenerman is currently President of CMC Biotech-MAS Consulting and the Graduate Program Director for the Masters in Biotechnology at the University of Maryland Baltimore County. He has also been an Adjunct Professor at Johns Hopkins University – Pharmacology and Molecular Medicines for the last 7 years. Prior to that, Schenerman spent more than 20 years in various roles in pharmaceutical development and regulatory processes at MedImmune/AstraZeneca. After receiving his Bachelor of Science degree in medical technology, he received his PhD in biochemistry & molecular biology from the University of Florida.
Schenerman’s volunteer positions with CASSS are extensive but highlights include serving as the Industry Co-Chair of WCBP and a member of the Global CMC Strategy Forum Steering Committee. He helped start many programs, including Bioassays, Higher Order Structure, DC Discussion Group, and CASSS Consultants' Network. He has also spearheaded CASSS’ involvement in the Hopkins Biotech Network Mentor Program. He has been recognized as a CASSS Distinguished Fellow for his outstanding contributions to CASSS, the community, and the industry overall.
In other changes to CASSS volunteer leadership, Sarah Kennett was elected Vice President and Secretary. Kennett is currently Executive Director, Regulatory Expert, Pharma Technical Regulatory at Genentech, a Member of the Roche Group. Prior to that, Kennett spent more than 12 years in various roles at the USA FDA, including Review Chief in the former Office of Biotechnology Products, OPQ/CDER, and in the former Office of Cell, Tissue, and Gene Therapy, CBER. After receiving her Bachelor of Science degree in molecular and cell biology from the Pennsylvania State University, Kennett received her PhD in molecular cancer biology from Duke University.
Kennett's long-standing service to CASSS includes key roles on the WCBP, CMC Strategy Forum North America, and CE Pharm program committees. She has contributed as a speaker, panelist, and workshop co-leader across numerous CASSS conferences, and was honored with the CE Pharm Award in recognition of her dedication to capillary electrophoresis and the CE Pharm meeting.
New board leadership positions and board members will begin their terms in January 2026.